China Biopharma to Buy 5% of Chia Tai Tianqing for RMB 4.48 Billion
China Biopharmaceutical (01177) will acquire an additional 5% stake in Chia Tai Tianqing for RMB 4.48 billion, lifting its indirect holding to 65% from 60%. Based on Chia Tai Tianqing's adjusted net profit attributable to shareholders for the 12 months to end-June 2026, the deal would add about 7.4%, or roughly RMB 350 million, to the group's adjusted attributable net profit. The shares rose as much as 4.1%.
China Biopharmaceutical (01177) announced that it will acquire a 5% stake in Chia Tai Tianqing by purchasing equity in the target company, for a consideration of RMB 4.48 billion. After completion, the company's indirect shareholding in Chia Tai Tianqing will rise to 65% from 60%.
Based on Chia Tai Tianqing's adjusted net profit attributable to shareholders for the 12 months ended June 2026, the acquisition would increase the group's adjusted net profit attributable to shareholders by about 7.4%, or approximately RMB 350 million. Chia Tai Tianqing focuses on the research and development, production and commercialisation of innovative and high-quality medicines, and is committed to providing patients with safe, effective and affordable treatment options on a sustained basis.
Shares of China Biopharmaceutical moved higher, gaining as much as 4.1% at one point to a high of HKD 5.465. As of 10:50 a. m. , the stock was at HKD 5.43, up 3.4%, with turnover of more than HKD 100 million.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 55/100 and 75% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.